<DOC>
	<DOC>NCT03018691</DOC>
	<brief_summary>To evaluate the safety, efficacy (dose response) and pharmacokinetics of 0.3% and 1% OPA-15406 when applied twice daily for 4 weeks in pediatric patients with atopic dermatitis.</brief_summary>
	<brief_title>Phase 2 Study of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Diagnosis of atopic dermatitis based on the criteria of Hanifin and Rajka Subjects who have an atopic dermatitis or contact dermatitis flareup defined as a sudden intensification of atopic dermatitis. Subjects who have an active viral skin infection. Subjects with a current or history of malignancy.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>